News Archive

As the Duke Clinical Research Institute (DCRI) celebrates Clinical Trials Day and we progress into the third year of the COVID-19 pandemic, we

A new study set out to determine the prevalence of tPA declination in a nationwide registry of acute ischemic stroke (AIS) patients and to investigate differences in declination by race-ethnicity. The results appear in a paper in the February 28 issue of Neurology entitled ‘Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke.’

A recent publication reports on an analysis of how study-specific fitness-for-use was addressed amongst pragmatic clinical trials that utilize real-world data (RWD), and makes recommendations to de

An industry emphasis on improving inclusion and diversity in clinical trials continues to grow, but strategies to achieve more balanced representation in research and clinical care remain elusive.

The DCRI celebrates its faculty members who recently received prestigious honors as part of Duke Medical School’s 2022 annual awards.

The goal of the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF; NCT02901184) is to assess the potential efficacy of mineralocorticoid receptor antagonists in these patients, and to evaluate the feasibility of the pragmatic trial concept for a chronic HF intervention. This is the first registry-based randomized clinical trial (RRCT) in heart failure, and among the first to focus on a chronic health condition.

COVID-19 health care workers experienced high rates of potential moral injury that are comparable to rates among military veterans, according to a collaborative study between Duke University, Vanderbilt University, and the Department of Veterans Affairs (VA).

Less than 30% of heart attack patients treated with cangrelor received the treatment in a way that was consistent with established protocols and the drug’s FDA labeling, according to new research from the Duke Clinical Research Institute using the CAMEO registry.

Medicare patients whose implantable heart devices became infected were less likely to die from the complication if they had the hardware removed compared to patients who only received antibiotics, according to the largest study on the topic, led by the Duke Clinical Research Institute.

A new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of the two. The study, led by cardiologists at the DCRI, was reported April 3 at the American College of Cardiology annual scientific sessions meeting and simultaneously published in the journal The Lancet.